Lärkberget (LARK) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
12 Feb, 2026Executive summary
Transitioned from a research-focused company to a pure investment company in 2025, marked by a name change and strategic shift.
Achieved a marginally positive result in H2 2025, attributed to cash flow-generating transactions.
Nasdaq removed the company's observation status in October 2025, eliminating delisting risk.
First major investment: acquired 12.9% of NAXS for 50 MSEK at a 39% NAV discount.
Distributed 0.20 SEK per share to shareholders, totaling 3.96 MSEK.
Financial highlights
Net sales for 2025: -252 TSEK (2024: 326 TSEK); other operating income: 1,066 TSEK (2024: 3,274 TSEK).
Result after financial items for 2025: -12,359 TSEK (2024: -48,958 TSEK).
Earnings per share for 2025: -0.62 SEK (2024: -2.47 SEK).
Cash flow for 2025: -69,767 TSEK (2024: -31,213 TSEK); cash at year-end: 2,594 TSEK (2024: 72,361 TSEK).
NAXS holding value increased by 3.57 MSEK (+7%) by year-end.
Outlook and guidance
No further costs from previous research projects expected from 2026 onward.
Focus on cash flow and NAV-driven investments; monthly NAV updates to be published.
NAV per share as of January 15, 2026: 3.08 SEK (+4.76% from November 2025).
Anticipated NAXS dividend in 2026 could yield 2.85 MSEK.
Latest events from Lärkberget
- Strategic shift to investment focus completed; strong cash, first investments imminent.LARK
Q2 202522 Aug 2025 - Strategic Partner A/S proposes a new board led by Luca Di Stefano for CombiGene.LARK
Investor Update13 Jun 2025 - Gene therapy focus sharpened, COZY prioritized, and cost cuts extend liquidity to 2026.LARK
Q3 202413 Jun 2025 - CG01 rights regained, CGT2 discontinued, COZY advanced; sales and cash declined year-over-year.LARK
Q2 202413 Jun 2025 - CombiGene halts R&D, posts SEK 44.9m loss, and shifts focus to investments or dividends.LARK
Q4 20245 Jun 2025